[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369144-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369144-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-state-of-the-art-review-of-the-recent-advances-of-theranostic-liposome-hybrid-nanoparticles-in-cancer-treatment-and-diagnosis","A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis","","Theranostics integrates diagnosis and therapy by using agents that are safe and non-toxic, selectively target cancer, and preferentially accumulate in malignant tissue. Liposomes are highlighted as an effective nanotechnology-based drug delivery platform, including stealth and commercial formulations. The review explains how multimodality imaging and liposomal therapeutic functions enable personalized monitoring of treatment response in vivo, while hybrid liposome–nanoparticle structures support combined therapeutic and imaging delivery. It evaluates advantages and limitations across liposome hybrid types and summarizes current research prospects for concurrent cancer detection and treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-state-of-the-art-review-of-the-recent-advances-of-theranostic-liposome-hybrid-nanoparticles-in-cancer-treatment-and-diagnosis/369144/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-state-of-the-art-review-of-the-recent-advances-of-theranostic-liposome-hybrid-nanoparticles-in-cancer-treatment-and-diagnosis/369144.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What criteria should ideal theranostic agents meet for cancer use?","Question",{"text":63,"@type":64},"They should be safe and non-toxic, able to treat cancer selectively, and able to accumulate in cancerous tissue.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are liposomes considered important in theranostic delivery?",{"text":68,"@type":64},"Liposomes are efficient nanotechnology-based drug delivery systems, with stealth and commercial forms influencing cancer treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"How do liposome–nanoparticle hybrid structures contribute to cancer therapy and diagnosis?",{"text":72,"@type":64},"Hybrid structures are discussed as useful for combining therapeutic and imaging methods, and they may show improved cancer-cell killing compared with liposomes alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369144,1790367556,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":107,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Azimizonuzi et al. Cancer Cell International (2025) 25:26 Cancer Cell International  \n[https://doi.org/10.1186/s12935-024-03610-z](https://doi.org/10.1186/s12935-024-03610-z)  \n REVIEW Open Access  \nA state-of-the-art review of the recent  \nadvances oftheranostic liposome hybrid nanoparticles in cancer treatment and diagnosis  \nHannaneh Azimizonuzi1, Arman Ghayourvahdat1, Mareb Hamed Ahmed2, Radhwan Abdul Kareem3, Athmar Jaber Zrzor4, Aseel Salah Mansoor5, Zainab H. Athab6 and Shaylan Kalavi7*  \nAbstract  \nTheranostics is a way of treating illness that blends medicine with testing. Specific characteristics should be present in the best theranostic agents for cancer: (1) the drugs should be safe and non-toxic; (2) they should be able to treat cancer selectively; and (3) they should be able to build up only in the cancerous tissue. Liposomes (LPs) are oneof the most efficient drug delivery methods based on nanotechnology. Stealth LPs and commercial LPs have recently had an impact on cancer treatment. Using the valuable information from each imaging technique, along with the multimodality imaging functionality of liposomal therapeutic agents, makes them very appealing for personalized monitoring of how well therapeutic drugs are working against cancer in vivo and for predicting how well therapies will work. On the other hand, their use as nanoparticle delivery systems is currently in the research and development phase. Nanoscale delivery system innovation has made LP-nanoparticle hybrid structures very useful for combining therapeutic and imaging methods. LP-hybrid nanoparticles are better at killing cancer cells than their LP counterparts, making them excellent options for in vivo and in vitro drug delivery applications. Hybrid liposomes (HLs) could be used in the future as theranostic carriers to find and treat cancer targets. This would combine the best features of synthetic and biological drug delivery systems. Overarchingly, this article provided a comprehensive overview of the many LP types used in cancer detection, therapy, and theranostic analysis. An evaluation of the pros and cons of the many HLs types used in cancer detection and treatment has also been conducted. The study also included recent and significant research on HLs for cancer theranostic applications. We conclude by outlining the potential benefits and drawbacks ofthis theranostic approach to the concurrent detection and treatment of different malignancies, as well as its prospects.  \nKeywords Liposome hybrids, Cancer, Theranostic, Detection, Treatment  \n*Correspondence: Shaylan Kalavi[shaylankalavi@gmail.com](shaylankalavi@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nAzimizonuzi et al. Cancer Cell International (2025) 25:26 Page 2 of 64  \nGraphical Abstract  \nIntroduction  \nCancer is ","cbCaihVqYdzEr9N3","https://ap.wps.com/l/cbCaihVqYdzEr9N3","pdf",3352126,64,"English","# Abstract\n# Introduction\n## Challenges in modern cancer therapy\n## Role of nanotechnology and nanoparticles\n# Theranostics and liposomal delivery principles\n# Liposome hybrids and hybrid nanoparticle delivery","[{\"question\":\"What criteria should ideal theranostic agents meet for cancer use?\",\"answer\":\"They should be safe and non-toxic, able to treat cancer selectively, and able to accumulate in cancerous tissue.\"},{\"question\":\"Why are liposomes considered important in theranostic delivery?\",\"answer\":\"Liposomes are efficient nanotechnology-based drug delivery systems, with stealth and commercial forms influencing cancer treatment.\"},{\"question\":\"How do liposome–nanoparticle hybrid structures contribute to cancer therapy and diagnosis?\",\"answer\":\"Hybrid structures are discussed as useful for combining therapeutic and imaging methods, and they may show improved cancer-cell killing compared with liposomes alone.\"}]","A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis | PDF",1790180971,161,[148,152,156,160,164,168,172],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f94972f95c88815d119b987f21d025bc.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07cf902ef1f1fbd0ee4c9e94d0ace85a.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83f37692d269b0cf9309f5984f3aa866.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4816b351b268bcfb2f2cb992276d6181.webp",980,1301,{"page_no":97,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29cb10475e63785a255bd7f996fb2c7b.webp",979,1300,{"page_no":102,"url":169,"width":170,"height":171},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/659cf8f635c60fe27c3abb7881ded944.webp",978,1299,{"page_no":107,"url":173,"width":174,"height":175},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48f38bedb4ccbb3ec61a430d755fad2a.webp",977,1297]